Hepatology and Gastrointestinal

Accelsiors is a recognized CRO in Gastrointestinal field, with special focus on Hepatology, with a very robust, 20+ years of experience in the field.

Collectively, GI disorders have a significant impact on global health and are highly prevalent worldwide. Hepatic disorders are prevalent worldwide. We have conducted several trials of all phases in indications like different forms of viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), cirrhosis, hepatic encephalopathy, hepatocellular carcinoma, autoimmune liver diseases (such as autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis), and genetic liver diseases (such as hemochromatosis and Wilson disease).

We are executing trials across all phases for a wide array of liver and GI conditions.

Contributing to enhanced understanding and improved management of these globally prevalent and impactful disorders.

Conditions such as liver disease, including viral hepatitis and liver cirrhosis, are significant causes of mortality. Gastrointestinal cancers, including those of the esophagus, stomach, liver, pancreas, and colorectal region, are leading causes of cancer-related deaths.

GI disorders can cause significant disability and harm the quality of life. Conditions like PBC, PSC, IBS, Crohn’s disease, and ulcerative colitis can result in chronic symptoms, recurrent flare-ups, and impairments in daily functioning and overall well-being. The burden and epidemiology of GI disorders may vary across different regions and populations. Some conditions, like certain liver diseases, are more prevalent in specific geographic areas due to viral hepatitis prevalence, lifestyle factors, or environmental exposures. Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, also exhibit regional variations in incidence and prevalence.